Prelude Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Prelude Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,673	Closed	-$1.22M	–	1300
2026 Q1	$1.22M	Buy	+56,673	New	+$799K	0.09%	257
2025 Q4	–	Sell	-10,641	Closed	-$75K	–	1351
2025 Q3	$75K	Sell	10,641 -8,898	-46%	-$61.2K	0.01%	1079
2025 Q2	$127K	Buy	+19,539	New	+$134K	0.01%	876
2024 Q1	–	Sell	-42,500	Closed	-$621K	–	1358
2023 Q4	$621K	Buy	42,500 +20,600	+94%	+$250K	0.04%	426
2023 Q3	$269K	Buy	21,900 +10,000	+84%	+$130K	0.02%	735
2023 Q2	$142K	Buy	+11,900	New	+$155K	0.01%	891

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's DAWN Position: Q2 2026 in Review

Prelude Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 56,673 shares — an estimated $1.22M sold.

Prelude Capital Management first reported a position in DAWN in Q2 2023 and held it in 6 quarters. The position peaked at $1.22M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Prelude Capital Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 56,673 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.22M.
Prelude Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 6 quarters.
Prelude Capital Management's Day One Biopharmaceuticals position peaked at $1.22M in Q1 2026.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.